ADT Booster Vaccine 0.5ml Syringe x5 (Diphtheria Tetanus Adult)

The ADT Booster Vaccine is a critical immunization product designed to protect adults against diphtheria and tetanus. This vaccine is administered as a booster dose to maintain immunity against these potentially life-threatening bacterial infections. The 0.5ml pre-filled syringes are designed for ease of use and ensure accurate dosing.

Product Specifications:
- Formulation: Each 0.5ml dose contains diphtheria toxoid and tetanus toxoid.
- Presentation: Pre-filled syringe, 0.5ml, supplied in packs of 5.
- Storage: Refrigerate between 2°C to 8°C. Do not freeze.
- Shelf Life: Check packaging for the expiration date; do not use beyond this date.
- Administration: Intramuscular injection, typically administered in the deltoid muscle.
- Safety: Single-use syringe to prevent cross-contamination and infection.

Common Applications:
- Adult Immunization: Recommended for adults requiring a booster for continued protection against diphtheria and tetanus.
- Travel Medicine: Essential for travelers to areas where diphtheria is endemic or where medical care is limited.
- Post-exposure Prophylaxis: May be used in certain situations following exposure to tetanus-prone injuries.

User Groups:
- Healthcare Workers: For protection in clinical settings where contact with patients may pose a risk of exposure.
- Adults Over 19: As a routine booster every 10 years, or as advised by healthcare professionals.
- Emergency Responders: For those who may be at increased risk of exposure due to their line of work.

Supplier Overview:
CSL Limited is a global biotechnology leader with over a century of experience in innovating and delivering breakthrough biotherapies. The company has established itself as an authority in the vaccine space, with a strong commitment to public health and safety. CSL's dedication to quality and its robust research and development capabilities make it a trusted supplier of vaccines, including the ADT Booster Vaccine. Their expertise in plasma-driven and recombinant technologies ensures that they are at the forefront of vaccine development and production, providing reliable and effective products to combat infectious diseases worldwide.